Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Ikena Oncology (IKNA) stocks

Learn how to easily invest in Ikena Oncology stocks.

Ikena Oncology is a biotechnology business based in the US. Ikena Oncology stocks (IKNA.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $13.33 – an increase of 4.91% over the previous week. Ikena Oncology employs 79 staff and has a trailing 12-month revenue of around $27.7 million.

How to buy stocks in Ikena Oncology

  1. Compare stock trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – IKNA – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of stocks with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Ikena Oncology stock price (NASDAQ:IKNA)

Use our graph to track the performance of IKNA stocks over time.

Ikena Oncology shares at a glance

Information last updated 2022-09-26.
Latest market close$3.63
52-week range$2.83 - $17.50
50-day moving average $4.90
200-day moving average $6.77
Wall St. target price$24.33
PE ratio 4.4625
Dividend yield $0 (0%)
Earnings per share (TTM) $0.80

Compare stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

1 - 5 of 5
Name Product Finder Rating Stock Trading Fee Account Fee Available Asset Types Offer
OFFER
CIBC Investor's Edge
Finder Rating:
★★★★★
4 / 5
$4.95–$6.95
$0 if conditions met, else $100/year
Stocks, Bonds, Options, Mutual Funds, ETFs
Young investors 18 to 24 can get free online trades and a $0 annual account fee. Conditions apply.
Interactive Brokers
Finder Rating:
★★★★★
4.1 / 5
min $1.00, max 0.5%
$0
Stocks, Bonds, Options, ETFs, Currencies, Futures
Questrade
Finder Rating:
★★★★★
4.2 / 5
$4.95 - $9.95
$0
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
Get $50 in free trades when you fund your account with a minimum of $1,000.
FREE TRADES
Wealthsimple
Finder Rating:
★★★★★
3.9 / 5
$0
$0
Stocks, ETFs
Get $25 when you open a Wealthsimple account and fund at least $150.
OFFER
Qtrade Direct Investing
Finder Rating:
★★★★★
4.1 / 5
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
Get almost $500 in commission free trades when you fund your new account with a minimum of $10,000. Conditions apply. Ends October 31, 2022.
loading

Compare up to 4 providers

Is it a good time to buy Ikena Oncology stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Ikena Oncology price performance over time

Historical closes compared with the close of $3.63 from 2022-09-27

1 week (2022-09-21) -4.47%
1 month (2022-08-29) -20.04%
3 months (2022-06-29) -18.97%
6 months (2022-03-29) -45.74%
1 year (2021-09-29) -67.82%
2 years (2020-09-25) N/A
3 years (2019-09-25) N/A
5 years (2017-09-25) N/A

Is Ikena Oncology under- or over-valued?

Valuing Ikena Oncology stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Ikena Oncology's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Ikena Oncology's P/E ratio

Ikena Oncology's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 4x. In other words, Ikena Oncology shares trade at around 4x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

However, Ikena Oncology's P/E ratio is best considered in relation to those of others within the biotechnology industry or those of similar companies.

    Ikena Oncology financials

    Revenue TTM $27.7 million
    Gross profit TTM $-16,123,000
    Return on assets TTM -12.66%
    Return on equity TTM -25.11%
    Profit margin -176.89%
    Book value $4.81
    Market capitalisation $145.4 million

    TTM: trailing 12 months

    Ikena Oncology share dividends

    We're not expecting Ikena Oncology to pay a dividend over the next 12 months.

    Ikena Oncology overview

    Ikena Oncology, Inc. , a targeted oncology company, focuses on developing medicines tailored to biomarker-defined patient groups for specific unmet needs. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway. It is also developing a small molecule inhibitor program against ERK5 in the RAS signaling pathway; IK-175, an oral inhibitor of aryl hydrocarbon receptor; and IK-007, an oral selective EP4 receptor antagonist for the treatment of microsatellite stable colorectal cancer. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts. .

    Frequently asked questions


    Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

    More on investing

    More guides on Finder

    Ask an Expert

    You must be logged in to post a comment.

    Go to site